Summit Therapeutics (SMMT) Revenue (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly Revenue came in at $220000.0 in Q3 2022, down 83.19% YoY from $1.3 million in Q3 2021, and down 6.38% on a QoQ basis from $235000.0 in Q2 2022.
Summit Therapeutics (SMMT) Revenue (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of Revenue data on file, last reported at $220000.0 in Q3 2022.
- Quarterly Revenue fell 83.19% year-over-year to $220000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $220000.0 (down 89.24% YoY) and the FY2022 annual result came in at $705000.0, down 61.03% from the prior year.
- Revenue retreated to $220000.0 in Q3 2022, from $235000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $50.6 million in Q3 2018 to a low of -$53.9 million in Q4 2019.
- A 5-year average of $584535.3 and a median of $227500.0 in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2018 — Revenue soared 725.33% — and 2019, when it slumped 99.68%.
- Tracing SMMT's Revenue over 5 years: stood at $876531.1 in 2018, then plunged by 6249.55% to -$53.9 million in 2019, then jumped by 100.34% to $185000.0 in 2020, then soared by 35.68% to $251000.0 in 2021, then retreated by 12.35% to $220000.0 in 2022.
- The last three Revenue figures came in at $220000.0 (Q3 2022), $235000.0 (Q2 2022), and $250000.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 220,000.00 |
| Jun 30, 2022 | 235,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 251,000.00 |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 57,000.00 |
| Mar 31, 2021 | 192,000.00 |
| Dec 31, 2020 | 185,000.00 |
| Sep 30, 2020 | 181,000.00 |
| Jun 30, 2020 | 170,000.00 |
| Mar 31, 2020 | 324,000.00 |
| Dec 31, 2019 | -53.90 Mn |
| Oct 31, 2019 | 153,473.53 |
| Sep 30, 2019 | 148,000.00 |
| Jul 31, 2019 | 159,750.29 |
| Mar 31, 2019 | 488,202.44 |
| Oct 31, 2018 | 876,531.05 |
| Jul 31, 2018 | 50.59 Mn |
| Apr 30, 2018 | 5.43 Mn |
| Jan 31, 2018 | 4.38 Mn |